Well-known pharmaceutical companies will change owners

Recently, De-Exhibition Health Co., Ltd. announced that the controlling shareholder Merrill Lynch Holdings Group Co., Ltd. and its co-actor Beijing Kaishi Fuller Asset Management Co., Ltd. - Kaiser Flor Steady No. 9 Private Equity Investment Fund and Xinjiang Kaidi Investment Co., Ltd. signed the "Share Transfer Framework Agreement."
if a formal agreement is finally signed and the delivery is completed, the actual controller of the company will be changed to the Xinjiang SASAC.
data show that many years ago, De-Zhang Health was a state-owned company, in 2016 Merrill Lynch Holdings through a major asset restructuring holding De-Exhibition Health, the company's actual controller changed from the Xinjiang SASAC to Merrill Lynch Holdings real controller Zhang , this time the Xinjiang SASAC took over, marking its official return to state-owned.
According to the announcement, the parties have tentatively reached the following agreement on the pricing principle of the proposed share transfer transaction: When the two parties sign the formal "Share Transfer Agreement", the transfer price per share of the shares to be transferred above shall remain valid, provided that they comply with the relevant provisions of laws and regulations and the relevant provisions of the regulatory authorities on the transfer price of shares of listed companies: Party B actively assists A Party 1 to solve its liquidity problem, after consultation with the banking and financial institutions, in principle, the first payment price of not less than 1.7 billion yuan, the remaining final payment will be resolved within 6 months after the first payment of the price, specifically by the parties will be in the "share transfer agreement" agreed in the specific payment method of the share transfer price.
website shows that De Zhanda Health focuses on cardiovascular drugs, anti-cancer oncology drugs, health care products, functional beverages, ecological water and other fields.
's subsidiary Jialin Pharmaceuticals is a well-known pharmaceutical company with great potential for development, the company to play the advantages of research and development, optimize the portfolio product structure, according to product development needs, the introduction of a variety of dosage forms to meet the production needs of production lines, increase injections, biopharmaceuticals, Chinese medicine preparations and other products, seize the development opportunities to open up the domestic and foreign generic drug market, seeking the development of generic drug preparation products in overseas markets.
note that the Framework Agreement on share transfer signed this time is only a framework agreement for the transfer of shares, the specific content of which is based on a separate formal agreement signed by the parties.
enter into this Agreement, the Transfered Party will conduct due diligence on the Company and, upon completion of the due diligence, determine whether to sign a formal share transfer agreement.
whether a formal agreement on the transfer of shares can be signed is uncertain.
jialin pharmaceutical industry, followed by easy main exhibition health of the main content is Jialin pharmaceutical heart and cerebrovascular drug research and development, production and sales.
mentioned That Jialin Pharmaceuticals, as a wholly-owned subsidiary of De-Exhibition Health, has for many years been ranked as the leading domestic drug in the market for blood-lowering drugs, and the main product "Ale" (common name: Atovastatin calcium tablets) is the first product in the country to pass a consistent evaluation.
2018, Ale successfully entered the 4-7 city centralized belt procurement, making it the focus of much debate in the industry, which also has a significant impact on the market for Atovastatin calcium tablets.
In order to successfully bid, Ale paid a price reduction of 83% to succeed in winning the bid - its average unit price in the centralized procurement area is 3.4 yuan / box, the average sales price in the non-centralized procurement area is 17.38 yuan / box.
according to the Chinese Pharmaceutical Society, in May 2019, "Al" has become the "4 plus 7" regional sample hospital Atovastatin calcium drug market share first.
Sales of "Ale", the main product in more than 1,300 sample hospitals nationwide, increased significantly in the market share of all three generic drugs, attovastatin, rhysovastatin and pivastatin, and increased by 10 percentage points in May 2019 compared to January 2019, ranking second among all three statins.
It should be noted, however, that during the nationwide expansion of the 4-7, Jialin Pharmaceuticals lost the bid, winning the bid for Qilu Pharmaceuticals, Lepu Medical and Xing'an Pharmaceuticals' triple-A generics companies.
the target price is: Qilu Pharmaceutical 1.68 yuan / tablet (10mg), Xin'an Pharmaceutical 3.6 yuan / tablet (28 tablets), Lepu 4.41 yuan / tablet (14 tablets), which compared to the previous price of 0.94 yuan / tablet, a further price reduction of 87.2%.
means that the nationwide market for attobastatin calcium will be reshuffled.
As a result, the 4-plus-7 cities and the country's enlargement areas, coupled with non-banded areas, there is a gap between procurement volume and price, which also has a greater impact on the company's overall revenue, the failure of the bid area and non-volume area dealers inventory decreased, but also to a certain extent caused by the decline in sales and sales.
This is directly reflected in the annual report on the health of de-exhibition, in 2019 the company achieved operating income of 1.77 billion yuan, a decrease of 46.06 percent yoY;
the bid, several media reports reported that Jialin Pharmaceuticals had fired its marketing staff because of its products in the 4-7 expansion.
, Carlin Pharmaceuticals responded that it had been relying on agents to promote it and did not have a dedicated sales team.
media later confirmed that the dissolution of the sales team is one of Jialin's two agents Hainan Corning.
it is understood that Hainan Corning has a number of regional promotion representatives have signed a separation agreement, and according to the N1 compensation.
In view of the current situation in the expansion of the bid, de-exhibition health in the 2019 annual report said: by the impact of the national volume procurement and other policies, Jialin Pharmaceutical production, sales adjustment, in the long run, the company and Jialin Pharmaceuticals only continue to broaden the product line, increase new profit points, in order to carry out continuous sustainable development.
Since 2019, de-exhibition health has expanded into innovative drugs, industrial cannabis products, cardiovascular screening and physical examination, represented by anti-tumor and anti-cancer pain, and is transitioning to diversified development, with the intention of developing new profit growth points, the future of state-owned enterprises or will continue to consolidate the company's transformation path, open a new round of performance growth space.
。